argenx (ARGX) Competitors

Sanofi (NASDAQ:SNY) and argenx (NASDAQ:ARGX) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, community ranking, valuation, analyst recommendations, earnings, media sentiment, profitability, institutional ownership and dividends.

Does the MarketBeat Community favor SNY or ARGX?

argenx received 613 more outperform votes than Sanofi when rated by MarketBeat users. Likewise, 67.61% of users gave argenx an outperform vote while only 60.92% of users gave Sanofi an outperform vote.

Company	Underperform	Outperform
Sanofi	Outperform Votes 53 60.92%	Underperform Votes 34 39.08%
argenx	Outperform Votes 666 67.61%	Underperform Votes 319 32.39%

Do insiders & institutionals believe in SNY or ARGX?

14.0% of Sanofi shares are held by institutional investors. Comparatively, 60.3% of argenx shares are held by institutional investors. 1.0% of Sanofi shares are held by company insiders. Comparatively, 2.4% of argenx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Does the media prefer SNY or ARGX?

In the previous week, Sanofi had 11 more articles in the media than argenx. MarketBeat recorded 23 mentions for Sanofi and 12 mentions for argenx. Sanofi's average media sentiment score of 0.87 beat argenx's score of 0.70 indicating that Sanofi is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sanofi	12 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
argenx	5 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has higher valuation & earnings, SNY or ARGX?

Sanofi has higher revenue and earnings than argenx. Sanofi is trading at a lower price-to-earnings ratio than argenx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanofi	$45.17B	2.76	$6.02B	$2.80	18.15
argenx	$2.58B	13.89	-$295.05M	$16.21	36.20

Do analysts prefer SNY or ARGX?

Sanofi currently has a consensus price target of $61.50, indicating a potential upside of 20.99%. argenx has a consensus price target of $709.18, indicating a potential upside of 20.86%. Given Sanofi's stronger consensus rating and higher probable upside, equities analysts clearly believe Sanofi is more favorable than argenx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanofi	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	3 Strong Buy rating(s)	3.13
argenx	0 Sell rating(s)	1 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	3.05

Is SNY or ARGX more profitable?

Sanofi has a net margin of 12.77% compared to argenx's net margin of -2.11%. Sanofi's return on equity of 25.61% beat argenx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanofi	12.77%	25.61%	14.72%
argenx	-2.11%	-1.45%	-1.29%

Which has more risk & volatility, SNY or ARGX?

Sanofi has a beta of 0.5, meaning that its stock price is 50% less volatile than the S&P 500. Comparatively, argenx has a beta of 0.39, meaning that its stock price is 61% less volatile than the S&P 500.

Summary

Sanofi beats argenx on 12 of the 19 factors compared between the two stocks.